Ionis director granted 10,753 stock options
Ionis Pharmaceuticals director Ludwig Hantson received a grant of non-qualified stock options covering 10,753 shares of common stock at an exercise price of $75.13 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ionis Pharmaceuticals director Ludwig Hantson received a grant of non-qualified stock options covering 10,753 shares of common stock at an exercise price of $75.13 per share. The options were granted at no cost as director compensation, vesting in three equal annual installments starting on June 4, 2027, and will be fully vested by June 4, 2029. The options expire on June 4, 2036, and were not exercisable as of the grant date.
Insider Trade Summary
Grant/Award: 10,753 shares
Grant/Award
1 txn
Insider
HANTSON LUDWIG
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 10,753 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 10,753 contracts (Direct)
Footnotes (1)
- F1. Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 06/04/2027. The option shall be fully vested and exercisable on 06/04/2029. The stock option was exercisable as to 0 shares on 06/04/2026.
Key Figures
Options granted: 10,753 options
Exercise price: $75.13 per share
Shares following transaction: 10,753 derivative securities
+5 more
8 metrics
Options granted
10,753 options
Non-qualified stock option grant on June 4, 2026
Exercise price
$75.13 per share
Strike price for underlying common stock
Shares following transaction
10,753 derivative securities
Total options held after this grant
Vesting start date
June 4, 2027
First one-third of options vest
Full vesting date
June 4, 2029
Options become fully vested and exercisable
Expiration date
June 4, 2036
Option term ends
Exercisable at grant
0 shares
Exercisable as of June 4, 2026
Grant price paid
$0.00 per option
Awarded as compensation, not purchased in market
Key Terms
Non-Qualified Stock Option (right to buy), Amended & Restated 2002 Non-Employee Directors' Stock Option Plan, vests and becomes exercisable, exercise price, +1 more
5 terms
Non-Qualified Stock Option (right to buy) financial
"security_title: Non-Qualified Stock Option (right to buy)"
Amended & Restated 2002 Non-Employee Directors' Stock Option Plan financial
"Grant of 06/04/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan."
vests and becomes exercisable financial
"The option vests and becomes exercisable in three equal annual installments"
exercise price financial
"conversion_or_exercise_price: 75.1300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-04T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ludwig Hantson receive in this Ionis (IONS) Form 4 filing?
Ludwig Hantson received a grant of 10,753 non-qualified stock options. These options give him the right to buy Ionis common shares at a fixed price as part of his compensation as a non-employee director.
What is the exercise price of Ludwig Hantson’s new Ionis stock options?
The options have an exercise price of $75.13 per share. This means Hantson can purchase Ionis common stock at $75.13 per share once the options vest and become exercisable, regardless of the future market price.
How do the 10,753 Ionis stock options granted to Ludwig Hantson vest?
The options vest in three equal annual installments beginning on June 4, 2027. One-third vests each year, and the grant will be fully vested and exercisable by June 4, 2029, assuming continued service as a non-employee director.
When do Ludwig Hantson’s Ionis stock options expire?
The non-qualified stock options expire on June 4, 2036. If Hantson does not exercise the vested options by that date, they will lapse and can no longer be used to purchase Ionis common stock under this award.
Were any of Ludwig Hantson’s Ionis options exercisable on the grant date?
No, none of the options were exercisable on the grant date of June 4, 2026. The filing states the stock option was exercisable as to 0 shares at that time, with vesting beginning one year later.
Under which plan were Ludwig Hantson’s Ionis options granted?
The options were granted under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. This plan provides equity-based compensation to outside directors instead of traditional cash-only fees.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates